Källkatalog — original

Ivermectin

• 1. Tang M, Hu X, Wang Y, et al. (2021)
  Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207.
  https://doi.org/10.1016/j.phrs.2020.105207 PubMed 32971268 PMC7505114
• 2. Robalino KN, et al. (2025)
  Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential. Pharmaceuticals. 2025;18(10):1459.
  DOI 10.3390/ph18101459 PubMed 41155573
• 3. Patel Y, et al.
  Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
  PubMed 40715995
• 4. Kaur B, et al. (2024)
  Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-Parasitic Therapy.
  PMC11008553
• 5. ClinicalTrials.gov NCT05318469
  Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
  https://clinicaltrials.gov/study/NCT05318469
• 6. ClinicalTrials.gov NCT07487805
  Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)
  https://clinicaltrials.gov/study/NCT07487805
• 7. Hulscher N, et al. (2026)
  Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.
  PubMed 42203321 Anticancer Research full text
• 8. The Nobel Prize (2015)
  The Nobel Prize in Physiology or Medicine 2015 — Campbell & Ōmura
  nobelprize.org

Mebendazole

• 9. Bai RY, et al. (2011)
  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
  Johns Hopkins / publication record
• 10. Gallia GL, et al. (2021)
  Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: Results of a phase 1 clinical trial.
  PMC7817892 NCT01729260
• 11. Patil VM, et al. (2022)
  Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. EClinicalMedicine. 2022;49:101449.
  DOI 10.1016/j.eclinm.2022.101449 PubMed 35747192
• 12–14. ClinicalTrials.gov
  NCT01837862 · NCT02644291 · NCT01729260
  NCT01837862 NCT02644291 NCT01729260

Fenbendazole

• 15. Dogra N, Kumar A, Mukhopadhyay T. (2018)
  Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018;8:11926.
  PubMed 30093705 PMC6085345
• 16. Park D, Lee JH, Yoon SP. (2022)
  Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean J Physiol Pharmacol. 2022.
  PMC9437363
• 17. Nguyen J, et al. (2024)
  Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research. 2024.
  ar.iiarjournals.org
• 18. Makis W, et al.
  Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration…
  PMC12215191
• 19. American Cancer Society
  What to Know About Fenbendazole
  cancer.org

USA — positiva originalkällor

• Dobrosotskaya IY, et al. (2011) — University of Michigan
  Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma.
  PubMed 21454232
• Bai RY, et al. (2011) — Johns Hopkins
  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
  Johns Hopkins
• Gallia GL, et al. (2021) — Johns Hopkins / NCT01729260
  Mebendazole and temozolomide in newly diagnosed high-grade gliomas: phase 1 (median OS 21 mo).
  PMC7817892
• NCT05318469 + ASCO 2025 e13146 — Cedars-Sinai
  Ivermectin + checkpoint inhibitor in metastatic TNBC (1 PR interim).
  NCT ASCO
• NCT07487805 — University of Florida (ICONIC)
  Ivermectin + immune checkpoint inhibition in solid tumors.
  ClinicalTrials.gov

→ Full USA-sida

Världen (Asien, Global South, integrativ)

• Heo DS (2020) — Korea
  Anthelmintics as potential anti-cancer drugs? Journal of Korean Medical Science.
  jkms.org
• Chai JY (2021) — Korea
  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.
  PMC8255490
• Kim JH et al. (2022) — Korea
  How cancer patients get fake cancer information (fenbendazole social phenomenon).
  PMC9650234
• Lei X et al. (2025) — China
  Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer… Molecules.
  DOI
• Jha SK et al. (2025) — India / Ayurveda integrativ
  A review on integrative approaches in oncology: bridging ayurvedic medicine and modern cancer therapeutics.
  Frontiers
• Pantziarka / ReDO (2014) — internationellt
  Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent.
  ecancer.org
• Shoda T et al. (1999) — Japan
  Liver tumor promoting effects of fenbendazole in rats.
  PubMed 10528635
• WHO Essential Medicines / Onchocerciasis
  Global MDA context for ivermectin (Africa, Latin America).
  eEML WHO fact sheet

→ Full världskarta på Världen-sidan

Utökade originalkällor (15-agent research 2026-07-29)

• Melotti A, et al. (2014)
  The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.
  DOI 10.15252/emmm.201404084
• Dou Q, et al. (2016)
  Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Research.
  DOI
• Draganov D, et al. (2021)
  Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. npj Breast Cancer. (Expression of Concern noterad 2026.)
  DOI
• ASCO 2025 abstract e13146
  Phase I/II ivermectin + balstilimab in metastatic TNBC — interim safety/efficacy (n=9).
  ascopubs.org
• Guzzo CA, et al. (2002)
  Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects.
  PubMed 12362927
• Duan Q, et al. (2013)
  Fenbendazole as a potential anticancer drug (null/negativ EMT6-modell).
  PubMed 23393324
• ClinicalTrials.gov NCT03925662 / NCT03628079
  Mebendazole colorectal combination RCT register; mebendazole GI monotherapy register.
  NCT03925662 NCT03628079
• FDA (2024) — veterinär varning
  Dear Veterinarian Letter regarding adverse events associated with extra-label use of fenbendazole in dogs (bone marrow hypoplasia/pancytopenia).
  fda.gov
• STROMECTOL (ivermectin) FDA label
  Full Prescribing Information — approved antiparasitic indications and dosing.
  FDA PDF

Full agentkatalog (~144 kB, alla 15 agenter): se research-mappen i workfoldern.

Regulatoriskt & varningar

• 20. U.S. FDA
  Ivermectin and COVID-19 (consumer update)
  fda.gov
• 21. ASCO Clinical Notice (2026)
  Recommending Against Ivermectin and Fenbendazole for Cancer Treatment (noterar samtidigt pågående trials)
  ASCO Connection